---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097548"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:00:38.779372+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Kalaris releases corporate presentation with TH103 trial updates but no specific figures disclosed

## Summary
- Presentation includes timelines for reporting Phase 1b/2 data of TH103 and plans to initiate Phase 3; no dates or numbers given in filing.
- Cash runway guidance mentioned in the presentation; precise amount or duration not provided in the 8-K.
- Presentation to be used at Leerink Partners Global Healthcare Conference and other investor meetings.

## SEC filing metadata
- accession: 0001193125-26-097548
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526097548/0001193125-26-097548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526097548/d122695d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097548
- JSON: https://secwatch.observer/filing/0001193125-26-097548.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.